Q1 2026 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2026-05-07 · accession 0001193125-26-210525
$336.0M
Reported value
9
Positions
2026-03-31
Period end
The Brief · Sanofi (SNY, SNYNF) · Q1 2026
AI · grounded in 13F
Sanofi SNY established a new position in Agomab Therapeutics NV AGMB with an investment of $29.2M. This addition increased the fund's total position count to 9. The fund reported total assets under management of $335.96M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $105.6M | 31.4% | 12,197,737 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $77.8M | 23.2% | 1,157,926 | Common | SOLE |
| 670002401 | NVAX | Novavax | $56.0M | 16.7% | 6,880,481 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $30.4M | 9.04% | 821,917 | Common | SOLE |
| 00860C102 | AGMB | Agomab Therapeutics NV | $29.2M | 8.69% | 2,783,096 | Common | SOLE |
| 56565P103 | MPLT | MapLight Therapeutics Inc. | $18.5M | 5.52% | 912,041 | Common | SOLE |
| 45254E107 | IMRX | Immuneering Corp | $14.3M | 4.25% | 2,708,559 | Common | SOLE |
| 28617K101 | ELDN | Eledon | $2.5M | 0.75% | 814,980 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $1.6M | 0.47% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.